An Activatable Caged Palladium Nanocomposite for Targeted Cancer Therapy.

Area of Science:

• Biomedical Engineering
• Nanotechnology
• Catalysis

Background:

• Palladium nanoparticles (Pd NPs) show promise for intracellular catalysis but suffer from low efficiency, poor solubility, and constant activity.
• Limitations include limited active sites and uncontrolled catalytic behavior, hindering therapeutic applications.

Purpose of the Study:

• To develop a high-performance palladium nanocomposite for enhanced intracellular catalysis and targeted disease treatment.
• To overcome the limitations of traditional Pd NPs through a cage-confined strategy.

Main Methods:

• Synthesized ultrafine Pd NPs confined within molecular cages.
• Incorporated glucose oxidase (GOx) and AS1411 aptamer-modified hyaluronic acid (HA).
• Evaluated targeting ability and activatable catalysis in response to tumor microenvironment factors (acidic pH, hyaluronidase).

Main Results:

• The cage-confined strategy yielded ultrafine Pd NPs with increased accessible active sites, boosting catalytic efficiency.
• The nanocomposite demonstrated targeted delivery and activatable catalysis, enabling selective drug synthesis in tumor environments.
• Exhibited CAT-, OXD-, and GPx-like activities, promoting ROS generation and GSH depletion for enhanced oxidative stress and therapy.

Conclusions:

• The developed nanocomposite offers a high-performance metal-based intracellular catalytic system.
• Cage confinement enhances Pd NP performance for bioorthogonal catalysis and targeted disease theranostics.
• This approach enables the synthesis of molecules for effective disease treatment and diagnosis.